ARS Pharmaceuticals neffy coverage securities class action
Analysis based on 174 articles · First reported Aug 06, 2026 · Last updated Sep 22, 2026
The lawsuits add legal and reputational pressure on ARS Pharmaceuticals after the June 2026 collapse in its share price tied to the delayed CVS Health coverage decision for neffy, keeping downside risk elevated for SPRY holders. Broader market impact is limited, as the matter is company-specific and confined to the specialty pharma and shareholder litigation space.
Multiple investor-rights law firms have filed securities class action lawsuits against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) and certain of its officers, alleging violations of federal securities laws during the class period of March 9, 2026 to June 24, 2026. The complaints allege that ARS made materially false and misleading statements and concealed material adverse facts regarding the expected timeline for expanded insurance coverage for neffy, its epinephrine nasal spray, through CVS Health. According to the complaints, ARS expressed confidence that coverage would begin on July 1, 2026 and be in place for the summer and back-to-school allergy seasons. On June 24, 2026, ARS reportedly announced that it did not receive expanded insurance coverage for neffy through CVS Health by the guided July 1, 2026 deadline, and that CVS Health reserved its decision until January 2027. On this news, ARS stock reportedly fell $2.52 per share, or 23.91%, to close at $8.02 per share on June 25, 2026. Law firms including Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Rosen Law Firm, and Schall Brown & Schwartz LLP have issued notices urging investors to seek lead plaintiff appointment before the October 5, 2026 deadline. No class has been certified.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard